AGT and diabetes mellitus: SGLT-2 inhibitors were found to induce a modest increase in plasma levels of aldosterone and AngII, but still within the low range typical in diabetes, as well as an increase in ACE2, ACE, and angiotensinogen (Kawanami et al., 2017).